Itraconazole is available as 100 mg capsules (Sporanox equivalent), Sporanox Oral Solution, 10 mg/ml, and Onmel 200 mg tablets. Itraconazole capsules and Sporanox oral solution may be obtained without a prior authorization. Onmel is only indicated for the treatment of onychomycosis of the toenail, requires prior authorization, and is subject to quantity limits.

**Prior Authorization Criteria for the Use of Onmel (itraconazole tablets)**

**One** of the following must be present, substantiated by office notes:
--- pain caused by onychomycosis
--- patient is a diagnosed diabetic
--- patient is immunocompromised
--- patient has peripheral vascular disease (PVD)

**In addition to the above**, the diagnosis of onychomycosis must be confirmed by positive results of **one** of the following:
--- KOH preparation (potassium hydroxide)
--- PAS stain (periodic acid-Schiff stain)
--- fungal culture (DTM-dermatophyte test medium)
Submit written positive results of test along with prior authorization form

When criteria is met, Onmel will only be approved for onychomycosis of the toenails. Maximum time of approval of Onmel for the treatment of onychomycosis is 12 weeks; quantity limits of 30 tablets/30 days for 3 months are in place.

The optimal clinical effect is seen months after mycological cure and cessation of treatment. The diseased nail will remain until replaced by a disease-free nail. Retreatment will not be considered for a period of 12 months.